Aptamers Market

Aptamers Market Outlook (2022-2030)

The global aptamers market has reached a valuation of US$ 2.4 billion in 2021. Progressing at a phenomenal CAGR of 21.6% over the next eight years, worldwide demand for aptamers is anticipated to rake in revenue worth US$ 11.5 billion by 2030.

Nucleic acid aptamers account for 77% of the global market share and are expected to maintain this dominant stance across the forecast period owing to increasing research on the use of nucleic acid aptamers in the treatment of several disorders.

Report Attributes	Details
Aptamers Market Size (2022)	US$ 2.4 Billion
Projected Market Value (2030F)	US$ 11.5 Billion
Global Market Growth Rate (2022-2030)	21.6% CAGR
North America Market Share (2022)	45%
Nucleic Acid Aptamers Market Share (2022)	77%
SELEX Technology Market Share (2022)	75%
Key Companies Profiled	Aptamer Sciences Inc. Somalogic Inc. Base Pair Biotechnologies Inc. Ophthotech Corporation Am Biotechnologies Aptamer Solutions Ltd. Aptus Biotech S.L. Neoventures Biotechnology Inc. Aptagen LLC Trilink Biotechnologies Inc. Vivonics Inc. Noxxon Pharma

Sales Analysis of Aptamers (2017-2021) in Comparison to Market Estimations (2022-2030)

Oligonucleotide aptamers can quickly bind target proteins with high specificity and are inexpensive in comparison to antibodies, which is expected to propel their demand over the coming years. The scope of application for aptamers has been widening in recent years and this trend is expected to follow through across the forecast period as well owing to increasing investments in the R&D of aptamers and aptamer technologies.

High prevalence of chronic diseases has increased the demand for novel diagnostic procedures and this has benefitted the aptamers market potential as aptamers are being used to create new diagnostic tests. The use of aptamers was briefly researched while developing rapid test kits for COVID-19 in 2020 and this has boosted the market potential for the years to come.

Rising awareness of the use of aptamers, increasing investments in aptamer R&D, low costs of aptamers, increasing approvals for aptamer therapeutics, and continual development of novel aptamer technologies are other factors that are expected to positively impact aptamers market growth potential through 2030.

However, lack of standardization, short half-life, low awareness in developing regions, and ethical concerns regarding animal-derived aptamers are some prospects that could impede demand for aptamers over the next eight years.

The market for aptamers is projected to exhibit evolution at an astronomical CAGR of 21.6% from 2022 to 2030.

This revised analysis by Fact.MR, a market research and competitive intelligence provider, details a comprehensive account of all the opportunities in the aptamers market, along with the drivers, restraints, and challenges, to gain a complete understanding of the current and forecasted industry scenario.

Why is Adoption of Aptamers Low?

“Lack of Standardization & Low Awareness in Developing Regions”

There’s a lack of universal regulatory guidelines that dictate the quality and safety of aptamers unlike other drugs and diagnostic tools. This factor is expected to slow down the demand for aptamers in developed regions such as North America and Europe. Stringent rules for approval in these regions are also predicted to hamper the overall market potential across the forecast period.

Lack of awareness about these molecules in developing and underdeveloped regions such as Asia Pacific, Middle East, and Africa is also anticipated to slow down sales of aptamers over the next eight years.

“Absence of Adequate Knowledge & Short Half-life”

Aptamers are relatively new and unexplored as compared to other molecules and there are still many characteristics of aptamers that are unknown to us, which hinders the adoption of aptamers. The low molecular weight of aptamers leads to rapid degradation of biological media and to avoid this there is a need for proper synthesis to keep its unwanted characteristics in check. These molecules have a very short half-life ranging from minutes to hours, which obstructs their practical application scope and hampers adoption across the world.

All of the aforementioned factors along with a lack of expertise to handle aptamers are expected to impede market potential throughout the forecast period.

What Can New Market Entrants Do to Make a Mark in This Industry?

“Product Innovation Should Be Prime Focus of New Aptamer Companies”

Aptamers are still relatively new to humans and there is a sea of unexplored potential in the aptamers marketplace owing to the nascent nature of this technology. New market players are expected to have a wide array of opportunities to create substantial space for themselves in this marketplace and they are expected to enhance their research scope to fast-track product innovation.

• In 2021, Xsensio, a Swiss digital health start-up collaborated with scientists at the Swiss Federal Institute of Technology Lausanne (EPFL) to create a new graphene-based sensing system that detects stress hormone called cortisol in human sweat. The system uses a patch that contains a graphene-based electrode and transistor. The graphene is functionalized through aptamers with a negative charge that captures cortisol when it comes in contact to measure the concentration in the user’s sweat.
• In December 2020, Basking Biosciences Inc., a privately-held biopharmaceutical organization announced the initial closing of a US$ 5.4 million seed series financing. The funding was used for the development of a next-generation treatment of acute ischemic stroke (AIS) which involved the use of DTRI-031, an RNA aptamer that inhibits von Willebrand Factor (vWF).

New companies are also focusing on acquiring new financing to expand their research and business scope across the world.

• In September 2022, Nutromics, an Australian medical technology start-up, raised US$ 14 million in funding. The funding will be used to expand the company’s R&D activities and clinical studies across Australia and the United States. The company is known for the development of its aptamer sensor which enables continuous monitoring with high accuracy.

What’s Stimulating Aptamers Market Growth across Geographies?

“Increasing Investments in R&D - Common Driver for All Regional Markets”

The market for aptamers in North America currently accounts for a dominant market share of 45% and is expected to maintain this stance across the forecast period owing to high investments in healthcare research and the presence of key market players in this region. Increasing establishment of research facilities and high incidence of chronic diseases are other trends in aptamers marketplace that could drive growth in this region.

The growth of the aptamers market in Europe is anticipated to be dependent on factors such as increasing approvals for advanced technologies and rising demand for aptamer therapies. The future of the aptamers market in this region is expected to be dependent on advancements in aptamer technologies by key market players.

The Asia Pacific aptamers market is projected to provide highly rewarding opportunities for established as well as new market players alike owing to loose regulatory mandates and efforts of key market players to explore the untapped potential in this region. Increasing investments in healthcare infrastructure development and supportive government initiatives are also expected to boost aptamers market potential over the next eight years.

Key developments in the aptamers industry in economies such as China, Japan, and India are expected to lead the overall growth in the Asia Pacific region through 2030.

Country-wise Insights

What’s Attracting Suppliers of Aptamers to the U.S.?

“High Spending on Research and Presence of Modern Healthcare Facilities”

The United States is known across the world for its matured healthcare infrastructure and developed healthcare research facilities that are equipped with state-of-art technologies and equipment. This makes it a highly attractive market for all healthcare research purposes and hence, provides a plethora of opportunities for aptamer companies.

Supportive government funding to advance research, the presence of key biotechnology and biopharmaceutical companies, rapid adoption of novel technologies, and high healthcare expenditure are other factors that could potentially uplift aptamers market growth through 2030.

Category-wise Insights

Why is SELEX the Gold Standard Technology in Aptamers?

“Continuous Advancements in SELEX Technique Makes it Crucial for Market Evolution”

The global aptamers market, based on technology, is segmented into SELEX, X-aptamers, MARAS technique, and others.

Systemic Evolution of Ligands by Exponential Enrichment (SELEX) technique has been used for a long time for the selection of aptamers, but the conventional technique involved time-consuming steps that would delay the whole selection process. To counter this, companies in the aptamers marketplace have been continuously investing in advancements of SELEX technologies, which is what drives the popularity of this technology in the industry landscape. The SELEX technology segment accounts for around 75% of the global market share at present.

Higher efficiency, simplified enzymatic steps, and faster selection are expected to be key prospects in driving the popularity of Magnetic-assisted Rapid Aptamer Selection (MARAS) techniques through 2030.

Competitive Landscape

Top aptamer companies are anticipated to focus on research and development of new aptamer-based products to strengthen their market stance.

• In November 2021, Achiko, a healthcare technology company announced the development of a new DNA aptamer-based dengue fever diagnostic test.

Key Segments in Aptamers Industry Research

• By Type :

  • Nucleic Acid Aptamers
    • DNA Aptamers
    • RNA Aptamers
    • XNA Aptamers
  • Peptide Aptamers

• By Application :

  • Diagnostics
  • Therapeutics
  • Research & Development
  • Others

• By Technology :

  • SELEX
  • X-aptamers
  • MARAS Technique
  • Others

• By End User :

  • Pharmaceutical & Biotechnology Companies
  • Academic & Government Research Institutes
  • CROs
  • Others

• By Region :

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA